Publication | Closed Access

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

AllergyImmunologyAllergenImmunodominanceTh2 ResponsesT Cell ImmunityHumoral ImmunityImmunoglobulin ETransient Tr1 ActivationImmunotherapyMedicineIge-blocking Antibodies